论文部分内容阅读
临床上对急、慢性呼吸衰竭、单纯缺氧血症或伴有高碳酸血症的药物治疗,多年来均沿用呼吸中枢兴奋剂,因其纠正血气障碍的效果并不确切,作用时间短,需反复用药且大剂量应用后又易致惊厥等,因此在呼吸衰竭的综合治疗措施中,使用呼吸兴奋剂并不占重要地位。1972年法国Laubie及Diot首次创用了一种新型呼吸兴奋药——阿米脱林(Almitrine,s2620,Vectarion),证实其为单纯的颈动脉窦及主动脉体周围化学感受器兴奋剂,该药能迅速提高PaO_2,降低PaCO_2,改善血气紊乱,即使应用较大剂量,亦不
Clinically, acute and chronic respiratory failure, simple hypoxemia or hypercapnia drug treatment, respiratory center stimulants are used over the years, because of its effect of correcting blood gas disorder is not precise, short duration, the need to be Repeated use of drugs and high-dose and easy to cause convulsions, etc. Therefore, the comprehensive treatment of respiratory failure, the use of respiratory stimulants does not occupy an important position. 1972 France Laubie and Diot for the first time created a new respiratory stimulant - Almitrine (Almitrine, s2620, Vectarion), confirmed that it is a simple carotid sinus and aortic peripheral chemoreceptor stimulants, the drug Can rapidly increase PaO_2, lower PaCO_2, improve blood disorder, even if the application of larger doses, nor